fda glp-1 warning 2025 november Drug Recalls and Warnings: Illegal Sales and Misleading Marketing by Novo Nordisk and Eli Lilly Trends In FDA FY 2025

Aims/hypothesis Regulators worldwide are reviewing safety data on glucagon-like peptide-1 receptor agonists (GLP-1RA), following reports by the Icelandic Medicines Agency in July 2023 of suicidal ideation and self-injury (SIS) in individuals taking liraglutide and semaglutide

Diverticulosismeans sm

Discovery requests and subpoenas can still pull you into the process, adding cost and disruption

Limited clinical evidence exists for fibromyalgia-specific pain relief with these medications

Understanding gastrointestinal risks, thyroid concerns, and patient-specific factors helps inform safer, more personalized treatment decisions with qualified healthcare provid

Patients who reduced the frequency of GLP-1 dosing (from weekly to every other week) were able to maintain their weight loss and metabolic syndrome gains, as reported in this case series